Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 07-2017 | 04-2017 | 01-2017 | 10-2016 | 09-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,928 | N/A | -14,401 | -6,755 | -16,342 |
| Depreciation Amortization | 32 | N/A | 29 | 19 | 117 |
| Accounts payable and accrued liabilities | 771 | N/A | -1,957 | -74 | -1,029 |
| Other Working Capital | 195 | N/A | -5,473 | -1,465 | 58 |
| Other Operating Activity | -518 | 0 | 721 | -1,565 | 3,236 |
| Operating Cash Flow | $-4,448 | $N/A | $-21,081 | $-9,840 | $-13,960 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -110 | N/A | -67 | -61 | -62 |
| Other Investing Activity | 0 | 0 | 34,139 | 0 | 0 |
| Investing Cash Flow | $-110 | $N/A | $34,072 | $-61 | $-62 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 2 | N/A | 7 |
| Other Financing Activity | 0 | 0 | 0 | 0 | -4,500 |
| Financing Cash Flow | $N/A | $N/A | $2 | $N/A | $-4,493 |
| Exchange Rate Effect | 64 | N/A | -1,259 | -1,177 | N/A |
| Beginning Cash Position | 30,950 | N/A | 21,764 | 21,764 | 53,723 |
| End Cash Position | 26,456 | N/A | 33,498 | 10,686 | 35,208 |
| Net Cash Flow | $-4,494 | $N/A | $11,734 | $-11,078 | $-18,515 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,448 | N/A | -21,081 | -9,840 | -13,960 |
| Capital Expenditure | -110 | N/A | -67 | -61 | -245 |
| Free Cash Flow | -4,558 | 0 | -21,148 | -9,901 | -14,205 |